Description

Revefenacin (CAS No. 864750-70-9) is a long-acting muscarinic antagonist (LAMA) with the molecular formula C₃₅H₄₃N₅O₄ and the IUPAC name [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate. This high-purity compound is specifically designed for research and pharmaceutical development, offering exceptional selectivity and potency in targeting muscarinic receptors. Revefenacin is supplied as a fine powder with guaranteed ≥98% purity (HPLC), ensuring reliability for in vitro and in vivo studies. Its low water solubility makes it ideal for formulation in organic solvents such as DMSO or ethanol. Suitable for COPD research, receptor binding assays, and pharmacokinetic studies, this product is rigorously tested for stability, endotoxin levels, and residual solvents to meet the highest industry standards.

Properties

• CAS Number: 864750-70-9
• Complexity: 918
• IUPAC Name: [1-[2-[[4-[(4-carbamoyl-1-piperidyl)methyl]benzoyl]-methyl-amino]ethyl]-4-piperidyl] N-(2-phenylphenyl)carbamate
• InChI: InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
• InChI Key: FYDWDCIFZSGNBU-UHFFFAOYSA-N
• Exact Mass: 597.33150487
• Molecular Formula: C35H43N5O4
• Molecular Weight: 597.7
• SMILES: CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
• Topological: 108
• Monoisotopic Mass: 597.33150487
• Solubility: < 1 mg/ml
• Synonyms: Revefenacin, TD-4208, Yupelri, GSK-1160724, revefenacina, revefenacine, GSK1160724, G2AE2VE07O, UNII-G2AE2VE07O, 1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl N-((1,1′-biphenyl)-2-yl)carbamate, TD4208, Biphenyl-2-ylcarbamic acid 1-(2-((4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl)methylamino)ethyl)piperidin-4-yl ester, Biphenyl-2-ylcarbamic acid, 1-(2-((4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl)methylamino)ethyl)piperidin-4-yl ester, Carbamic acid, N-(1,1′-biphenyl)-2-yl-, 1-(2-((4-((4-(aminocarbonyl)-1-piperidinyl)methyl)benzoyl)methylamino)ethyl)-4-piperidinyl ester, revefenacinum, R03BB08, 864750-70-9, Revefenacin [INN], 1-(2-(3-((4-carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1′-biphenyl]-2-ylcarbamate, Revefenacin [WHO-DD], 864750-70-9 (free base), [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate, 1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1′-biphenyl]-2-ylcarbamate, TD-4208; GSK-1160724;[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate, Carbamic acid, N-[1,1′-biphenyl]-2-yl-, 1-[2-[[4-[[4-(aminocarbonyl)-1-piperidinyl]methyl]benzoyl]methylamino]ethyl]-4-piperidinyl ester; Carbamic acid, [1,1′-biphenyl]-2-yl-, 1-[2-[[4-[[4-(aminocarbonyl)-1-piperidinyl]methyl]benzoyl]methylamino]ethyl]-4-, Yupelri (TN), Revefenacin (Standard), REVEFENACIN [MI], Revefenacin (USAN/INN), Revefenacin [USAN:INN], REVEFENACIN [USAN], Revefenacin;GSK1160724, SCHEMBL356480, CHEMBL3833319, GTPL10129, REVEFENACIN [ORANGE BOOK], DTXSID701027775, GLXC-23321, HMS3886K17, HMS5084F21, Revefenacin [USAN:INN:WHO-DD], BCP15793, EX-A1722, HY-15851R, s5258, AKOS037649398, CCG-270187, CS-7743, DB11855, SB17262, BS-18189, DA-57407, FR178690, HY-15851, TD-4208?, NS00073361, D10978, EN300-20352165, Q27278649, Revefenacin; TD 4208; TD4208; GSK-1160724; GSK1160724; GSK 1160724, 1-[2-(1-{4-[(4-carbamoylpiperidin-1-yl)methyl]phenyl}-N-methylformamido)ethyl]piperidin-4-yl N-{[1,1′-biphenyl]-2-yl}carbamate, 1211931-83-7, TD-4208;1-(2-(3-((4-carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1-biphenyl]-2-ylcarbamate

Application

Revefenacin is primarily used as a long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). It functions by inhibiting bronchoconstriction, thereby improving lung function and reducing symptoms. Researchers utilize Revefenacin in preclinical and clinical studies to investigate its efficacy and safety profile. It is also employed in receptor binding assays to study muscarinic receptor interactions and signaling pathways.

Safety and Hazards

GHS Hazard Statements

• H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
• H312 (100%): Harmful in contact with skin [Warning Acute toxicity, dermal]
• H332 (100%): Harmful if inhaled [Warning Acute toxicity, inhalation]

Precautionary Statements

• P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501

Hazard Classes and Categories

• Acute Tox. 4 (100%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.